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Background: Metastatic penile carcinoma derived from cholangiocarcinoma (CCA) has not been previously
reported in the literature. Common metastatic sites for CCA include the regional lymph nodes and adjacent organs.
CCAs are not highly vascularised tumours, making hematogenous metastases uncommon. Hematogenous CCA
metastases commonly occur at distant organs such as the lungs, adrenal glands, and bones. Median survival for
patients with metastatic disease is generally less than 1 year.
Case presentation: A 74-year-old Caucasian man consulted us after having undergone penile ultrasonography for
pain and increased thickness at the base of the penis after self-examination. The patient presented with a history of
hepatitis C-related cirrhosis and intrahepatic CCA, diagnosed 3 years previously. A biopsy of the corpora cavernosa
on both sides revealed a carcinoma harbouring the same histological and immunophenotypical features as the
primary hepatic lesion.
Conclusions: To date, there is no case of penile or urogenital system metastasis from CCA described in the
literature. Therefore, this article represents the first case report of penile metastasis from CCA.
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Cholangiocarcinoma (CCA) is an uncommon and ag-
gressive malignancy that originates in the bile duct epi-
thelium and is associated with very poor prognosis [1].
The incidence and risk factors of CCA vary in different
regions of the world. The highest incidence is reported
in the north-eastern part of Thailand. The major risk
factor for CCA in this area is Opisthorchis viverrini in-
fection, whereas Clonorchis sinensis is associated with
CCA in Korea and China [2]. Other risk factors for CCA
are primary sclerosing cholangitis; biliary-duct cysts;
hepatolithiasis; and conditions such as hepatitis B infec-
tion, hepatitis C infection, obesity, chronic non-alcoholic
liver disease, and cirrhosis [3]. The incidence of CCA
peaks during the sixth decade of life and shows a slight
male predominance. Tumours most frequently occur at* Correspondence: antonioluigi.pastore@uniroma1.it
1Department of Medico-Surgical Sciences and Biotechnologies, Urology Unit,
ICOT Latina, Sapienza University of Rome, Latina, Italy
Full list of author information is available at the end of the article
© 2013 Pastore et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orthe confluence of the hepatic ducts and are classified as
hilar CCAs or Klatskin tumours.
The most common physical indications of CCA include
symptoms such as jaundice, dyspepsia, and a palpable ab-
dominal mass [1]. Symptoms of CCA depend on whether
the tumour mass is located in the intrahepatic area, hilar
area, or extrahepatic area. Surgical intervention plays a
major role in the treatment of early stage CCA and yields
promising results. Patients with unresectable tumours
can be treated with palliative procedures such as biliary-
enteric bypass or endoscopic or percutaneous stent place-
ment. Palliative surgical bypass is associated with a slightly
improved survival rate compared to percutaneous trans-
hepatic biliary drainage. Palliative chemotherapy does not
show significant benefits, as survival rates remain low [4].
Common metastatic sites of CCA include the regional
lymph nodes and adjacent organs. Distant metastases
from CCA are uncommon, but when they do occur, they
usually develop in the bone, muscle, brain, and thyroid
gland [5-7]. To our knowledge, no other cases of penileLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ture. Here, we report the case of a patient who presented
with penile metastatic CCA and who was treated in our
institution. We aim to provide useful information on this
extremely rare condition.
Case presentation
A 74-year-old Caucasian man consulted us after having
undergone penile ultrasonography for pain and in-
creased thickness at the base of the penis after self-
examination. The patient presented with a history of
hepatitis C-related cirrhosis and intrahepatic CCA, diag-
nosed 3 years previously, when he underwent right pos-
terior hepatic subsegmentectomy with lymph node
dissection. No portal vein invasion had been reported,
and all lymph nodes had been negative. The patient had
not received adjuvant therapy after surgery. Follow-up
examinations had been performed every 3 months for
2 years post-operatively and every 6 months thereafter.
The patient had undergone clinical examination, labora-
tory tests including measurement of tumour markers,
abdominal ultrasonography, and radiological investiga-
tions including chest and abdominal computed tomog-
raphy. Twenty-nine months after the primary surgery,
follow-up positron emission tomography-computed tom-
ography had not revealed any elevation in the standar-
dised uptake value at any site.
Penile ultrasound examination, performed with a high-
frequency linear probe (12–5 MHz), showed a large solid
formation located at the base of the penis with poorly
defined edges involving the corpora cavernosa on both
sides and the corpus spongiosum of the urethra, without
invasion of the tunica albuginea. Elastography showed
discrete intralesional vascularity with a high strain ratio
of 22. The thickness of the septum between the corporaFigure 1 Evidence of large anelastic area in correspondence of the so
intercavenospongiousus septum with normal elasticity of peripheralcavernosa and corpus spongiosum was increased due
to calcification on the distal two-thirds of the length
(Figure 1).
Magnetic resonance imaging (MRI; Figure 2) showed a
mass surrounding the left corpus spongiosum on both
dorsal and ventral sides of the tunica albuginea, with in-
volvement of Buck’s fascia. On post-contrast images, the
mass showed a slight and tardive enhancement, suggesting
a fibrous composition. The urethra was displaced with
partial infiltration. MRI was performed without the injec-
tion of alprostadil because of the patient’s pain.
Discrete intralesional vascularity was also observed.
Therefore, we decided to perform a biopsy of the corpora
cavernosa on both sides via skin incision at the root of the
penis. Histologic analysis revealed a carcinoma harbouring
the same histological and immunophenotypical features as
the primary hepatic lesion. Histopathologic analysis re-
vealed a malignant epithelial neoplasm composed of cu-
boidal or columnar cells with pleomorphic nuclei and
prominent nucleoli as well as weakly eosinophilic cyto-
plasm organised in duct-like structures (Figures 3 and 4).
The neoplastic cells were positive for CK7, CK 8/18,
CK19, CK 20, epithelial membrane antigen (EMA), and
carcinoembryonic antigen (CEA) and negative for Heppar-1
and CD56 [8,9].
Discussion
CCAs form a heterogeneous group of tumours that de-
velop along the biliary tract, arising from different topo-
graphic regions of the biliary tree. Depending on their
site of origin, they have different features and require
different specific treatments. The occurrence of most
CCAs is sporadic. Patients with CCA often present with
non-specific symptoms such as cachexia, abdominal
pain, night sweats, and fatigue. Blood tests that can belid lesion located at the level of the corpora cavernosa and the
tissues.
Figure 2 MRI of the penis. A) T2 weighted image shows a ipointense tissue sorrounding the left corpus spongiosum (arrow) and arising dorsal
and ventral side of tunica albuginea; Buck’s fascia was also involved on the left side (arrowhead). B) Unenhanced axial T1-weighted MR image
showing hypointense nodular lesions (arrows) on the left corpus spongiosum with irregular margins. C-D) Sagittal and axial T1-weighted MR
images with fat signal suppression, after Gadolinum injection, show slight enhancement of the corrisponding tissue on A and B, as we expected
on predominant fibrous matrix. None involvement of perivisceral fat was noted.
Figure 3 High-power photomicrograph showing metastatic
cholangiocarcinoma composed by duct-like structures lined by
cuboidal or columnar cells with high pleomorphism,
surrounded by dense stromal reaction (magnification 40×).
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serum levels are often elevated in these patients, but
these measurements are not sufficiently sensitive or spe-
cific to be used as a general screening tool. However, they
may be useful in conjunction with imaging methods, in
order to support the diagnosis of a suspected CCA. The
common metastatic sites for CCA are the regional lymph
nodes (hilar, peripancreatic, and periaortic lymph nodes)
and adjacent organs. CCAs are not highly vascularised tu-
mours, making haematogenous metastases uncommon.
Haematogenous CCA metastases commonly occur at dis-
tant organs such as the lungs, adrenal glands, and bones.
Patients with a history of CCA may also develop meta-
static disease several years after first presentation. For this
reason, the onset of new symptoms or signs requires ad-
equate investigation in these patients, and a possible meta-
static occurrence should be considered in order to treat it.
In cases of diagnostic doubt, biopsy and histopathology
combined with immunophenotypical tests should lead to
an accurate diagnosis and prognosis for the patient.
Figure 4 High-power photomicrograph showing immunoreactivity of metastatic (A-F) cholangiocarcinoma; the neoplastic cells
resulted negative for Heppar-1 (A) and positive for CK7 (B), CK19 (C), CK 20 (D), EMA, (E) and CEA (F) (magnification 40×).
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mary sites are the genitourinary tract (mainly, bladder
urothelial cancer and prostate adenocarcinoma) and the
lower gastrointestinal tract (especially, rectum and sigmoid
colon). Most cases of penile metastasis are metachronous
(i.e. prostate, urothelial cancers, etc.).
The most common observed symptoms and signs of
metastasis to the penis in order of frequency are priap-
ism (up to 40%, resulting from emboli or thrombosis of
dorsal vein, defined as “malignant priapism”), urinary re-
tention, penile nodules, ulcer formation, perineal pain
(7–10%), oedema, generalised swelling, broad infiltrative
enlargement, dysuria, and haematuria (less than 10%).
The diagnosis in our patient was achieved by ultra-
sound and MRI that showed the presence of a solid
lesion, which was localised in the corpora cavernosa
without any involvement of the tunica albuginea and
with extensive calcification of the intercavernous and
intercavernospongious septa. Moreover, in our case,
there were no clinical suspicious or laboratory data (PSA
levels, hematuria, etc.), suggestive for malignancies that
most frequently metastasize to the penis, such as pros-
tate cancer and urothelial carcinoma.
Several mechanisms by which a tumour can secondarily
affect the penis have been described; apart from the retro-
grade lymphatic route of spread, venous retrograde spread
is the most common route, owing to the generous com-
munication between the pelvic venous plexuses and the
penile dorsal venous system [7§-9§]. Direct tumour ex-
tension has also to be considered a possible mechanism
of tumour involvement.
The penile metastasis diagnosis must be established on
biopsy, as was performed in this case. To differentiate me-
tastatic lesions from primary penile tumours, an adequate
specimen is needed as early as possible. It is important,
though, to differentiate primary penile carcinoma from
secondary metastatic disease since primary tumours are
curable in a high percentage of cases.
The time interval between primary tumour and penile
metastasis ranges from 3 months to 5 years and the time
interval between diagnosis of penile metastasis and deathranges from 0.25 to 18 months. In our patient, metastasis
became evident 3 years after the diagnosis of intrahepatic
CCA. Because penile involvement by a secondary tumour
usually indicates systemic dissemination, the prognosis is
poor. In previously reported series, most of the patients
died between 6 months and 1 year after the detection of
the penile metastasis [10]. All treatments may be con-
sidered palliative, as published clinical cases report im-
provement of patient symptoms without any important
prolongation in survival. Prolonged survival is often
possible only when a distal penile lesion or nodule is re-
sectable; limited surgical excision or radiotherapy is usu-
ally the most useful modality. Partial or total penectomy
will be required with highly invasive neoplasms involving
the corporal bodies.
Conclusions
To date, there is no case of penile or urogenital system
metastasis from CCA described in the literature. There-
fore, to our knowledge this article represents the first
case report of penile metastasis from CCA.
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